Literature DB >> 17084243

Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement.

Willibald Hochholzer1, Dietmar Trenk, Hans-Peter Bestehorn, Benjamin Fischer, Christian M Valina, Miroslaw Ferenc, Michael Gick, Angelika Caputo, Heinz Joachim Büttner, Franz-Josef Neumann.   

Abstract

OBJECTIVES: Our prospective study tested the hypothesis that the 30-day clinical outcome of elective percutaneous catheter intervention (PCI) differs between strata defined by quartiles of platelet aggregation after loading with 600 mg clopidogrel.
BACKGROUND: Platelet responses after loading with clopidogrel are highly variable. The impact of this variability on the peri-interventional risk of patients undergoing PCI has not been investigated prospectively.
METHODS: Our study included 802 consecutive patients undergoing elective coronary stent placement. Before PCI, patients received a loading dose of 600 mg clopidogrel followed by 75 mg daily. Primary end point was the 30-day composite of death, myocardial infarction, and target lesion revascularization (major adverse cardiac events [MACE]). Platelet aggregation was assessed immediately before PCI by optical aggregometry (5 micromol/l adenosine diphosphate).
RESULTS: During 30-day follow-up, 15 patients (1.9%) incurred MACE (3 deaths, 8 myocardial infarctions, 8 target lesion revascularizations). Quartiles of platelet aggregation were <4%, 4% to 14%, 15% to 32%, and >32%. Thirty-day MACE differed significantly (p = 0.034) between quartiles of platelet aggregation. It was 0.5% in the first quartile, 0.5% in the second, 3.1% in the third, and 3.5% in the fourth. Platelet aggregation above the median carried a 6.7-fold risk (95% confidence interval 1.52 to 29.41; p = 0.003) of 30-day MACE. Multivariable logistic regression analysis, including pertinent covariables, confirmed platelet aggregation as a significant independent predictor of 30-day MACE (adjusted odds ratio per 10% increase in platelet aggregation 1.32, 95% confidence interval 1.04 to 1.61; p = 0.026).
CONCLUSIONS: The level of platelet aggregation immediately before elective coronary stenting in patients pre-treated with a high loading dose of clopidogrel is correlated with early outcome after the procedure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17084243     DOI: 10.1016/j.jacc.2006.06.065

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  90 in total

1.  Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention.

Authors:  Patrik Htun; Suzanne Fateh-Moghadam; Christian Bischofs; Winston Banya; Karin Müller; Boris Bigalke; Konstantinos Stellos; Andreas E May; Marcus Flather; Meinrad Gawaz; Tobias Geisler
Journal:  J Am Soc Nephrol       Date:  2011-01-27       Impact factor: 10.121

2.  Correlation of high post-treatment platelet reactivity assessed by light transmittance aggregometry and the VerifyNow P2Y12 assay.

Authors:  In-Suk Kim; Young-Hoon Jeong; Min-Kyung Kang; Jin-Sin Koh; Yongwhi Park; Seok-Jae Hwang; Choong Hwan Kwak; Jin-Yong Hwang; Sunjoo Kim
Journal:  J Thromb Thrombolysis       Date:  2010-11       Impact factor: 2.300

3.  Prophylactic Antiplatelet Medication in Endovascular Treatment of Intracranial Aneurysms: Low-Dose Prasugrel versus Clopidogrel.

Authors:  E J Ha; W S Cho; J E Kim; Y D Cho; H H Choi; T Kim; J S Bang; G Hwang; O K Kwon; C W Oh; M H Han; H S Kang
Journal:  AJNR Am J Neuroradiol       Date:  2016-07-07       Impact factor: 3.825

Review 4.  Personalized vascular medicine: individualizing drug therapy.

Authors:  Emil M Degoma; Giovanni Rivera; Scott M Lilly; M Haris U Usman; Emile R Mohler
Journal:  Vasc Med       Date:  2011-10       Impact factor: 3.239

Review 5.  The evolution of antiplatelet therapy in cardiovascular disease.

Authors:  Omair Yousuf; Deepak L Bhatt
Journal:  Nat Rev Cardiol       Date:  2011-07-12       Impact factor: 32.419

6.  Drug-eluting coronary stents: as safe as bare-metal stents, but optimized antiplatelet therapy may further improve clinical outcome.

Authors:  Dietmar Trenk; Franz-Josef Neumann
Journal:  Eur J Clin Pharmacol       Date:  2007-12-13       Impact factor: 2.953

Review 7.  High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance.

Authors:  Torkom Garabedian; Samir Alam
Journal:  Cardiovasc Diagn Ther       Date:  2013-03

8.  Effects of persistent platelet reactivity despite aspirin therapy on cardiac troponin I and creatine kinase-MB levels after elective percutaneous coronary interventions.

Authors:  Oyku Gulmez; Aylin Yildirir; Gamze Kaynar; Didem Konas; Alp Aydinalp; Cagatay Ertan; Bulent Ozin; Haldun Muderrisoglu
Journal:  J Thromb Thrombolysis       Date:  2007-06-16       Impact factor: 2.300

9.  Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients.

Authors:  Henrik Wagner; Dominick J Angiolillo; Jurrien M Ten Berg; Thomas O Bergmeijer; Joseph A Jakubowski; David S Small; Brian A Moser; Chunmei Zhou; Patricia Brown; Stefan James; Kenneth J Winters; David Erlinge
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

Review 10.  Monitoring aspirin and clopidogrel response: testing controversies and recommendations.

Authors:  Athanasios Karathanos; Tobias Geisler
Journal:  Mol Diagn Ther       Date:  2013-06       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.